카테고리 없음
Mavacamten Phase III clinical trial, FDA nod for Ovarian cancer therapy, Dyno Therapeutics & Novartis Collaboration, Abbott’s COVID-19 diagnostic kit
anjrawat
2020. 5. 13. 23:03
- MyoKardia has announced the promising results of Phase III clinical trials of its lead drug Mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
- AstraZeneca and Merck’s Lynparza (olaparib) in combination with Roche’s Avastin (bevacizumab) receives FDA approval for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
- Dyno Therapeutics has announced the launch of its proprietary CapsidMap platform to design novel adeno-associated virus (AAV) vectors.
- Abbott Laboratories has won EUA for its diagnostic kit – SARS-CoV-2 IgG lab-based serology blood test on the Alinity i system for COVID-19.
For more detailed information visit:
https://www.delveinsight.com/blog/recent-pharma-happenings-for-astrazeneca-abbott-merck-myokardia/